BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28860494)

  • 1. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
    Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
    Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization of novel quinolone chalcone compounds by a structure-activity relationship (SAR) study to increase efficacy and metabolic stability.
    Knockleby J; Djigo AD; Lindamulage IK; Karthikeyan C; Trivedi P; Lee H
    Sci Rep; 2021 Nov; 11(1):21576. PubMed ID: 34732782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
    Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
    J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
    Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
    Lin MS; Hong TM; Chou TH; Yang SC; Chung WC; Weng CW; Tsai ML; Cheng TR; Chen JJW; Lee TC; Wong CH; Chein RJ; Yang PC
    Eur J Med Chem; 2019 Nov; 181():111584. PubMed ID: 31419740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
    Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
    J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
    Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
    Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
    Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
    J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular effects of curcumin on Plasmodium falciparum include disruption of microtubules.
    Chakrabarti R; Rawat PS; Cooke BM; Coppel RL; Patankar S
    PLoS One; 2013; 8(3):e57302. PubMed ID: 23505424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
    Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
    Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
    Wang G; Peng F; Cao D; Yang Z; Han X; Liu J; Wu W; He L; Ma L; Chen J; Sang Y; Xiang M; Peng A; Wei Y; Chen L
    Bioorg Med Chem; 2013 Nov; 21(21):6844-54. PubMed ID: 23993668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.
    Ning N; Yu Y; Wu M; Zhang R; Zhang T; Zhu C; Huang L; Yun CH; Benes CH; Zhang J; Deng X; Chen Q; Ren R
    Cancer Res; 2018 Oct; 78(20):5949-5957. PubMed ID: 30135190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
    Chen J; Wang Z; Li CM; Lu Y; Vaddady PK; Meibohm B; Dalton JT; Miller DD; Li W
    J Med Chem; 2010 Oct; 53(20):7414-27. PubMed ID: 20919720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
    Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
    Loganzo F; Hari M; Annable T; Tan X; Morilla DB; Musto S; Zask A; Kaplan J; Minnick AA; May MK; Ayral-Kaloustian S; Poruchynsky MS; Fojo T; Greenberger LM
    Mol Cancer Ther; 2004 Oct; 3(10):1319-27. PubMed ID: 15486199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrostatic contributions to colchicine binding within tubulin isotypes.
    Huzil JT; Barakat K; Tuszynski JA
    Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.